Akua Graf, James Welch, Rashika Bansal, Adel Mandl, Vaishali I Parekh, Craig Cochran, Elliot Levy, Naris Nilubol, Dhaval Patel, Samira Sadowski, Smita Jha, Sunita K Agarwal, Corina Millo, Jenny E Blau, William F Simonds, Lee S Weinstein, Jaydira Del Rivero
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may occur in 30% to 90% of patients with multiple endocrine neoplasia type 1 (MEN1). However, only 1% of GEP-NETs are grade 3 (G3). Given the rarity of these aggressive tumors, treatment of advanced G3 GEP-NETs in MEN1 is based on the treatment guidelines for sporadic GEP-NETs. We report a 43-year-old male with germline MEN1 followed at our institution, with clinical features including hyperparathyroidism, a nonfunctional pancreatic NET, and Zollinger-Ellison syndrome...
October 1, 2022: Journal of the Endocrine Society